A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication

Area of Science:

• Oncolytic virotherapy
• Molecular virology
• Cancer biology

Background:

• Oncolytic viruses (OVs) are engineered to selectively infect and kill cancer cells.
• Achieving tumor specificity is crucial for safe and effective clinical application of OVs.
• MicroRNA dysregulation is a common characteristic of cancer cells.

Purpose of the Study:

• To engineer a replication-competent vesicular stomatitis virus (VSV) for tumor-specific replication.
• To utilize differential microRNA expression in cancer cells as a mechanism for viral targeting.
• To enhance the safety profile of oncolytic viruses by reducing off-target toxicity.

Main Methods:

• Engineered vesicular stomatitis virus (VSV) by incorporating let-7 microRNA complementary sequences.
• Assessed viral replication and toxicity in cancer cells versus normal cells in vitro.
• Evaluated the efficacy and tumor specificity of the engineered VSV in vivo.

Main Results:

• Engineered VSV with let-7 complementary sequences showed significantly reduced replication in normal cells.
• The modified VSV demonstrated robust replication in cancer cells, both in vitro and in vivo.
• This approach successfully eliminated undesirable replication and associated toxicity in normal tissues.

Conclusions:

• Exploiting cancer-specific microRNA expression is a viable strategy for designing tumor-specific oncolytic viruses.
• Engineered VSV demonstrates proof of concept for microRNA-targeted oncolytic virotherapy.
• This approach holds potential for optimizing OV gene expression for enhanced antitumor activity and safety.